Miraca Holdings is taking over the anatomic pathology business run by Caris Diagnostics (CDx), a unit of Caris Life Sciences (CLS), and its subsidiaries and affiliates. The transaction will be valued at $725 million, including repayment of the existing debt, subject to customary post-closing price adjustments.

The deal does not include CLS’ Caris Target Now molecular profiling service or Carisome circulating microvesicle technology, presently under development. The acquisition is part of Miraca’s plan to expand its business globally and will also expand its footprint in the U.S. laboratory testing market.

Click here for the release from Globe Newswire.